There have been reports of pulmonary aspiration (when food or liquid from the stomach enters the lungs) in people taking GLP-1 medications, including Zepbound while undergoing surgery requiring sedation, even when instructed to fast before the surgery
1,2 Current therapies for HS, including adalimumab, secukinumab, bimekizumab, oral and topical antibiotics, and anti-inflammatory agents, fail to address one of the root causes, the metabolic and inflammatory burden, which could be an important driver of the disease
Pharmacological considerations currently focus on managing associated metabolic and cardiovascular conditions rather than directly treating the liver
Naimi RM, Hvistendahl M, Nerup N, Ambrus R, Achiam MP, Svendsen LB, et al